RT Conference Proceedings
T1 Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC
A1 Mok, T.
A1 Nakagawa, K.
A1 Rosell, R.
A1 Lee, K.
A1 Corral, J.
A1 Migliorino, M. R.
A1 Pluzanski, A.
A1 Linke, R.
A1 Devgan, G.
A1 Sbar, E.
A1 Quinn, S.
A1 Wang, T.
A1 Wu, Y.
K1 dose reduction
K1 non-small cell lung cancer
K1 Dacomitinib
PB Elsevier science inc
SN 1556-0864
YR 2018
FD 2018-10-01
LK https://hdl.handle.net/10668/27249
UL https://hdl.handle.net/10668/27249
LA en
DS RISalud
RD Apr 17, 2025